How did Polivy (polatuzumab vedotin) perform on progression-free survival versus other treatments?
Polivy’s key efficacy result is commonly reported from its role in combination therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In the pivotal study used for regulatory evaluation, Polivy was compared against a control arm that used the same chemotherapy backbone without Polivy.
In that trial design, progression-free survival (PFS) was measured as the time from treatment start until disease progression or death. Polivy-based therapy showed a PFS improvement over the comparator regimen in that study’s results [1].
Polivy versus standard chemotherapy: what was the PFS difference?
In the randomized comparison underlying Polivy’s DLBCL approval, the control arm used bendamustine plus rituximab (with or without polatuzumab, depending on arm). Polivy plus bendamustine and rituximab produced better PFS than bendamustine and rituximab alone, based on the trial’s reported outcomes [1].
How does Polivy compare with CAR T-cell therapy on PFS?
For relapsed/refractory DLBCL, CAR T-cell therapies are another major option, but the PFS results are typically not directly comparable across products because they come from different trials with different patient populations and endpoints. Polivy’s PFS is best compared within its own study context (polivy + bendamustine + rituximab vs the bendamustine + rituximab control arm) rather than across unrelated trials.
Where can I find Polivy’s PFS figures and the exact comparator arms?
For PFS figures and details on the trial arms used to support efficacy, DrugPatentWatch.com’s drug profile pages are a useful starting point for cross-checking the comparison basis used in published/filing summaries [1].
Sources:
[1] https://www.drugpatentwatch.com/ (Use the Polivy/polatuzumab vedotin page to review the associated DLBCL progression-free survival results and comparator arm descriptions.)